Press Release: Omnicell to Release Second Quarter 2026 Financial Results on July 30, 2026

Dow Jones

07/14

FORT WORTH, Texas--(BUSINESS WIRE)--July 13, 2026--

Omnicell, Inc. (Nasdaq:OMCL), a leading healthcare technology provider focused on empowering autonomous medication management, will release its financial results for the second quarter 2026, before market open on Thursday, July 30, 2026. The Company will host a conference call and webcast to discuss its financial results at 8:30 a.m. ET that same day.

All interested parties are invited to listen to the live call and presentation by dialing (833) 461-5787 in the U.S. or (585) 542-9983 in international locations. The Conference ID is 656119963. A link to the live and archived webcast will also be available on the Investor Relations section of Omnicell's website at https://ir.omnicell.com/events-and-presentations/.

About Omnicell

Since 1992, Omnicell has been committed to delivering innovative, outcomes-centric pharmacy and nursing solutions for all settings of care. As an intelligent medication management technology company, Omnicell empowers autonomous medication management by unifying automation and AI-enabled intelligence, optimized by expert services, to drive clinical and business outcomes that are helping to improve efficiency and enhance patient safety for healthcare facilities worldwide. Learn more at omnicell.com.

OMNICELL and the Omnicell logo are registered trademarks of Omnicell, Inc. or one of its subsidiaries.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260713793931/en/

 
    CONTACT:    Investor Relations Contact

David Unger

Omnicell, Inc.

ir@omnicell.com

(END) Dow Jones Newswires

July 13, 2026 16:24 ET

應版權方要求，你需要登入查看該內容

登入 / 註冊

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hant/news/2651412001"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2651412001\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2651412001?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-14 04:24","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2651412001","market":"sh","top_or_hot":-1,"title":"Press Release: Omnicell to Release Second Quarter 2026 Financial Results on July 30, 2026","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\nFORT WORTH, Texas--(BUSINESS WIRE)--July 13, 2026-- \n</pre>\n<p>\n     <a href=\"https://laohu8.com/S/OMCL\">Omnicell</a>, Inc. (Nasdaq:OMCL), a leading healthcare technology provider focused on empowering autonomous medication management, will release its financial results for the second quarter 2026, before market open on Thursday, July 30, 2026. The Company will host a conference call and webcast to discuss its financial results at 8:30 a.m. ET that same day. \n</p>\n<p>\n     All interested parties are invited to listen to the live call and presentation by dialing (833) 461-5787 in the U.S. or (585) 542-9983 in international locations. The Conference ID is 656119963. A link to the live and archived webcast will also be available on the Investor Relations section of Omnicell's website at https://ir.omnicell.com/events-and-presentations/. \n</p>\n<p>\n     About Omnicell \n</p>\n<p>\n     Since 1992, Omnicell has been committed to delivering innovative, outcomes-centric pharmacy and nursing solutions for all settings of care. As an intelligent medication management technology company, Omnicell empowers autonomous medication management by unifying automation and AI-enabled intelligence, optimized by expert services, to drive clinical and business outcomes that are helping to improve efficiency and enhance patient safety for healthcare facilities worldwide. Learn more at omnicell.com. \n</p>\n<p>\n     OMNICELL and the Omnicell logo are registered trademarks of Omnicell, Inc. or one of its subsidiaries. \n</p>\n<p>\n     View source version on businesswire.com: https://www.businesswire.com/news/home/20260713793931/en/ \n</p>\n<pre style=\"white-space: pre\">\n \n    CONTACT:    Investor Relations Contact \n</pre>\n<p>\n     David Unger \n</p>\n<p>\n     Omnicell, Inc. \n</p>\n<p>\n     ir@omnicell.com \n</p>\n<pre style=\"white-space: pre\">\n \n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>July 13, 2026 16:24 ET</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Press Release: Omnicell to Release Second Quarter 2026 Financial Results on July 30, 2026</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPress Release: Omnicell to Release Second Quarter 2026 Financial Results on July 30, 2026\n</h2>\n<h4 class=\"meta\">\n<div class=\"head\" \">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time smaller\">2026-07-14 04:24</p>\n</div>\n</div>\n</h4>\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\nFORT WORTH, Texas--(BUSINESS WIRE)--July 13, 2026-- \n</pre>\n<p>\n     <a href=\"https://laohu8.com/S/OMCL\">Omnicell</a>, Inc. (Nasdaq:OMCL), a leading healthcare technology provider focused on empowering autonomous medication management, will release its financial results for the second quarter 2026, before market open on Thursday, July 30, 2026. The Company will host a conference call and webcast to discuss its financial results at 8:30 a.m. ET that same day. \n</p>\n<p>\n     All interested parties are invited to listen to the live call and presentation by dialing (833) 461-5787 in the U.S. or (585) 542-9983 in international locations. The Conference ID is 656119963. A link to the live and archived webcast will also be available on the Investor Relations section of Omnicell's website at https://ir.omnicell.com/events-and-presentations/. \n</p>\n<p>\n     About Omnicell \n</p>\n<p>\n     Since 1992, Omnicell has been committed to delivering innovative, outcomes-centric pharmacy and nursing solutions for all settings of care. As an intelligent medication management technology company, Omnicell empowers autonomous medication management by unifying automation and AI-enabled intelligence, optimized by expert services, to drive clinical and business outcomes that are helping to improve efficiency and enhance patient safety for healthcare facilities worldwide. Learn more at omnicell.com. \n</p>\n<p>\n     OMNICELL and the Omnicell logo are registered trademarks of Omnicell, Inc. or one of its subsidiaries. \n</p>\n<p>\n     View source version on businesswire.com: https://www.businesswire.com/news/home/20260713793931/en/ \n</p>\n<pre style=\"white-space: pre\">\n \n    CONTACT:    Investor Relations Contact \n</pre>\n<p>\n     David Unger \n</p>\n<p>\n     Omnicell, Inc. \n</p>\n<p>\n     ir@omnicell.com \n</p>\n<pre style=\"white-space: pre\">\n \n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>July 13, 2026 16:24 ET</p>\n</font>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4082","symbol_name":"醫療保健設備","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2651412001","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2651412001","pubTimestamp":1783974240,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"FORT WORTH, Texas--(BUSINESS WIRE)--July 13, 2026--Omnicell, Inc. (Nasdaq:OMCL), a leading healthcare technology provider focused on empowering autonomous medication management, will release its finan","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4082":"医疗保健设备","OMCL":"Omnicell","BK4167":"医疗保健技术"},"translate_title":"新闻稿：Omnicell 将于 2026 年 7 月 30 日发布 2026 年第二季度财务业绩","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"OMCL":1.5},"content_text":"FORT WORTH, Texas--(BUSINESS WIRE)--July 13, 2026-- \n\n\nOmnicell, Inc. (Nasdaq:OMCL), a leading healthcare technology provider focused on empowering autonomous medication management, will release its financial results for the second quarter 2026, before market open on Thursday, July 30, 2026. The Company will host a conference call and webcast to discuss its financial results at 8:30 a.m. ET that same day. \n\n\n     All interested parties are invited to listen to the live call and presentation by dialing (833) 461-5787 in the U.S. or (585) 542-9983 in international locations. The Conference ID is 656119963. A link to the live and archived webcast will also be available on the Investor Relations section of Omnicell's website at https://ir.omnicell.com/events-and-presentations/. \n\n\n     About Omnicell \n\n\n     Since 1992, Omnicell has been committed to delivering innovative, outcomes-centric pharmacy and nursing solutions for all settings of care. As an intelligent medication management technology company, Omnicell empowers autonomous medication management by unifying automation and AI-enabled intelligence, optimized by expert services, to drive clinical and business outcomes that are helping to improve efficiency and enhance patient safety for healthcare facilities worldwide. Learn more at omnicell.com. \n\n\n     OMNICELL and the Omnicell logo are registered trademarks of Omnicell, Inc. or one of its subsidiaries. \n\n\n     View source version on businesswire.com: https://www.businesswire.com/news/home/20260713793931/en/ \n\n\n \n    CONTACT:    Investor Relations Contact \n\n\n     David Unger \n\n\n     Omnicell, Inc. \n\n\n     ir@omnicell.com \n\n\n \n \n\n\n  (END) Dow Jones Newswires\n\nJuly 13, 2026 16:24 ET","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"0","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"need_login_tip":false,"code":"91000000","status":"200"}}}